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Fibrosis is a pathological process characterized by massive deposition of extracellular 
matrix (ECM) such as type I/III collagens and fibronectin that are secreted by an 
expanded pool of myofibroblasts, which are phenotypically altered fibroblasts with 
more contractile, proliferative, migratory and secretory activities. Fibrosis occurs in 
various organs including the lung, heart, liver and kidney, resulting in loss of normal 
tissue architecture and functions. Myofibroblasts could originate from multiple sources 
including tissue-resident fibroblasts, epithelial and endothelial cells through 
mechanisms of epithelial/endothelial-mesenchymal transition (EMT/EndMT), and bone 
marrow-derived circulating progenitors called fibrocytes. Emerging evidence in recent 
years shows that sphingosine-1-phosphate (S1P) acts on several types of target cells and 
is engaged in pro-fibrotic inflammatory process and fibrogenic process through multiple 
mechanisms, which include vascular permeability change, leukocyte infiltration, and 
migration, proliferation and myofibroblast differentiation of fibroblasts. Many of these 
S1P actions are receptor subtype-specific. In these actions, S1P has multiple cross-talks 
with other cytokines, particularly transforming growth factor-β (TGFβ), which plays a 
major role in fibrosis. The cross-talks include the regulation of S1P production through 
altered expression and activity of sphingosine kinases in fibrotic lesions, altered 
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expression of S1P receptors, and S1P receptor-mediated transactivation of TGFβ 
signaling pathway. These cross-talks may give rise to a feed-forward, amplifying loop 
between S1P and TGFβ, and possibly with other cytokines in stimulating fibrogenesis. 
Another lysophospholipid mediator lysophosphatidic acid has also been recently 
implicated in fibrosis. The lysophospholipid signaling pathways represent novel, 
promising therapeutic targets for treating refractory fibrotic diseases. 
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Fibrosis is usually associated with chronic inflammation induced by various stimuli 
including infections, immune reactions, chemical irritation, mechanical injuries and 
irradiation, and involves massive deposition of extracellular matrix (ECM) including 
type I and III collagens, fibronectin, elastin and proteoglycan by an expanded 
fibroblastic pool [1, 2]. Fibrosis occurs in various organs and tissues including the heart, 
lung, liver, kidney and skin, resulting in distorted organ architecture and serious 
dysfunction. For example, the development of fibrosis in the heart causes increased 
stiffness of the myocardium and aberrant signaling within myocardium, resulting in 
progressive cardiac failure [3]. Pulmonary fibrosis disrupts normal alveolar architecture 
and impairs gas exchange with reduced vital capacity and oxygen diffusion [4]. Liver 
fibrosis (cirrhosis) leads to hepatic failure and portal hypertension. 
   Fibroblasts are the key cells that are involved in fibrogenesis [1-3]. In healthy 
tissues, fibroblasts are quiescent; they primarily maintain ECM component homeostasis 
by regulating synthesis and degradation of ECM. In the process of fibrosis, injured 
epithelial and non-epithelial cells release cytokines that attract inflammatory cells to 
primary sites of insult. Infiltrating inflammatory cells then release additional cytokines 
that provoke further damages in the tissues and also stimulate fibroblasts to migrate, 
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proliferate and secrete de novo ECM components (Figure 1) [5]. Fibroblasts thus 
activated at sites of fibrogenesis acquire smooth muscle features including elevated 
expression of α-smooth muscle actin (αSMA) and increased contractility [1-5]. These 
contractile fibroblasts are termed myofibroblasts. Myofibroblasts can originate from 
various cell types including tissue-resident fibroblasts, epithelial and endothelial cells 
through processes of epithelial/endothelial-mesenchymal transition (EMT/EndMT), 
vascular pericytes, and bone marrow-derived circulating fibroblast-like cells termed 
fibrocytes, but most are likely generated from tissue-resident stromal fibroblasts [1,4-6].   
Among various cytokines and growth factors implicated in fibrogenesis, 
transforming growth factor-β (TGFβ), which is released from damaged parenchymal 
cells, inflammatory cells and myofibroblasts themselves, potently induces 
myofibroblastic differentiation and promotes the synthesis of ECM, playing a pivotal 
role in fibrogenesis [5]. TGFβ is also one of the most powerful inducer of EMT. 
Connective tissue growth factor (CTGF) is another fibrogenic cytokine that acts 
downstream of TGFβ and enhances TGFβ-driven responses. Platelet-derived growth 
factor (PDGF) is a powerful mitogen and chemoattractant for fibroblasts. Other 
cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6 and 
vasoactive peptides including endothelin and angiotensin II (Ang II) are also implicated 
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in myofibroblastic differentiation and their activation, thus fibrogenesis. 
   Sphingosine-1-phosphate (S1P) is a blood-borne lysophospholipid mediator that 
exerts a variety of activities including the regulation of cell migration, proliferation and 
differentiation. S1P research during the past two decades has elucidated well 
appreciated, diverse actions of S1P, which, however, may not yet reflect the whole 
picture of pleiotropic actions of this enigmatic mediator. S1P was initially shown to be 
potently mitogenic for fibroblasts in the early 90’s [7]. Subsequently, S1P was also 
found to regulate migration of fibroblasts [8, 9]. More recently, S1P was shown to 
induce a myofibroblastic phenotype through trans-activating TGFβ signaling pathway 
[10]. Furthermore, S1P maintains vascular barrier integrity and regulates leukocyte 
trafficking [11], thus playing an important role in regulating inflammation, which 
underlies fibrosis when it is prolonged. In fact, recent studies (see below) reported the 
findings to suggest that S1P signaling pathway is involved in fibrotic diseases. This 
article reviews current knowledge of the role of S1P signaling pathway as a novel key 
factor in understanding cellular and molecular mechanisms of fibrosis in various organs.  
 
Cardiac fibrosis 
In the myocardium, the S1P-synthesizing enzymes sphingosine kinases (SphKs) and 
7 
 
S1P receptors S1P1, S1P2 and S1P3 are expressed, with the order of reported abundance 
in receptor subtypes being S1P1>> S1P3> S1P2 for cardiomyocytes and S1P3>> S1P1> 
S1P2 for cardiac fibroblasts (CFs) [12]. In vasculature, S1P1 and S1P3 are predominantly 
expressed in endothelial cells to mediate eNOS stimulation and vasorelaxation [13, 14], 
whereas S1P2 and S1P3 are the major subtypes in smooth muscle to mediate 
vasocontraction via Ca2+ mobilization and Rho activation [13, 15, 16]. Whether S1P 
induces vasorelaxation or contraction in a vascular bed could be determined largely by 
the S1P receptor subtype expression and the balance between vasodilator and constrictor 
signals. It was demonstrated that S1P induced relaxation of rat coronary artery as an 
overall effect, which was mediated mainly via endothelial S1P3 [17], whereas S1P 
reduced coronary perfusion in mice independently of eNOS [18]. In the heart, acute S1P 
(and its carrier HDL) action is cardioprotective against ischemia/reperfusion injury [12, 
14, 19, 20 for review], which has attracted much attention from researchers of both 
basic and clinical medicine. S1P protects cultured rat neonatal cardiomyocytes from 
ischemia-induced cell death [21] and suppresses ischemia/reperfusion injury ex vivo 
[22]. In vivo studies using S1P receptor-null mice showed that S1P3, either alone [14] or 
in combination with S1P2 [23], mediates cardioprotective effect of S1P and HDL against 
ischemia/reperfusion injury (Figure 2). The cardioprotective action of S1P3 seems to 
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involve S1P3-mediated activation of endothelial NO synthase (eNOS) [14]. Studies 
using mice with genetic deletion of SphK1 [24] and SphK2 [25] demonstrated that 
endogenous S1P, either in perfusates or in cardiac tissues, is cardioprotective ex vivo. 
S1P generation in the heart is upregulated in response to a transient ischemia, 
suggesting the contribution of the SphK-S1P axis to ischemic preconditioning and 
ischemic post-conditioning [26]. Mice heterozygous for deletion of the S1P-degradating 
enzyme S1P lyase gene and wild-type mice receiving an SPL inhibitor, which showed 
elevated S1P levels in both plasma and cardiac tissues, had reduced sensitivity to 
ischemia/reperfusion injury, raising a possibility of cardioprotection with an S1P lyase 
inhibitor in clinical settings [27]. However, a recent study provided evidence that excess 
S1P signaling for prolonged period of time could rather exert a deleterious effect, i.e. 
promote cardiac fibrosis. 
In the normal human adult heart cardiac fibroblasts (CFs) are the most abundant cell 
type and constitute approximately 60% of total cells in cardiac tissues while  
cardiomyocytes occupy 30% and the remaining 10% are vascular endothelial and 
smooth muscle cells [28]. This fact suggests crucial roles of CFs in normal cardiac 
physiology. CFs originally stem from the proepicardium during embryonic stage [29]. 
Just after birth under a drastic hemodynamic change, CFs rapidly proliferate and 
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actively produce ECM in neonatal heart, thus beginning to provide structural support 
against mechanical stretch and ensure myocardial integrity, which persists lifelong with 
constant and steady-state turnover of ECM. In addition, although CFs are not an 
excitable cell type, they communicate with cardiomyocytes via gap junctions, and 
electrically respond to mechanical stretch with cyclical changes in the membrane 
potential [30, 31], thus contributing to synchronized excitation of atria and ventricles. 
Upon ischemia and I/R injury acute derangements in cellular functions of 
cardiomyocytes and CFs could lead to generation of fatal arrhythmia. After survival 
through acute myocardial infarction CFs proliferate and produce ECM to form a scar 
tissue that substitutes for necrotic and apoptotic loss of cardiomyocytes to achieve 
cardiac repair. In a variety of chronically ill conditions of ischemic and non-ischemic 
etiology, CFs respond to external stimuli with phenotypic changes, which include 
increased cell proliferation, migration, and changes in production and degradation of 
ECM, depending upon external stimuli that are as diverse as mechanical stretch, altered 
oxygen tension, proinflammatory and profibrotic cytokines and growth factors [32]. 
CFs thus activated or myofibroblasts produce a variety of bioactive substances, which in 
turn act in an autocrine/paracrine fashion on cardiomyocytes and CFs themselves, 
provoking cardiac fibrosis with or without cardiomyocyte hypertrophy and functional 
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decompensation. Myofibroblasts in cardiac remodeling may be derived from circulating 
bone marrow-derived fibrocytes and epithelial cells through EMT, in addition to 
resident CFs which originally stem from the proepicardium during embryonic stage [33]. 
Deposition of myofibroblast-derived ECM including abundant type I/III fibrillar 
collagen confers stiffness to myocardium, which leads to impaired cardiac relaxation 
and contraction, i.e. heart failure. CFs/myofibroblasts thus play the major role in 
pathological cardiac remodeling and represent a target of therapeutic intervention.   
   Previous studies have shown that local renin-angiotensin-aldosterone system (RAS) 
and TGFβ play crucial roles in inducing pathological cardiac remodeling [32, 34]. 
Cardiomyocytes and CFs express all the components of RAS. Myofibroblasts are the 
major source of Ang II, which induces synthesis and secretion of TGFβ and other 
proinflammatory and profibrotic cytokines including TNFα, IL-6, and endothelin-1 
(ET-1) through AT1 receptor (AT1R). TGFβ induces Smad-dependent transcriptional 
upregulation of connective tissue growth factor and collagen synthesis [35]. TGFβ 
signaling in the heart may also be transactivated by Ang II [36]. AT1R activation in 
cardiomyocytes induces activation of the Rho family small GTPases, RhoA and Rac1, 
leading to cardiac remodeling including hypertrophy and fibrosis [37]. Rac1 activation 
is located upstream of NADPH oxidase-mediated production of ROS [38], a mediator of 
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cardiac remodeling. Moreover, AT1R activation in vascular endothelial cells inhibits 
eNOS through a Rho-dependent mechanism [39], which could participate in cardiac 
fibrosis. These mechanisms provide the molecular basis for well established treatment 
for pathological cardiac remodeling and heart failure with AT1R blockers (ARB) or 
angiotensin converting enzyme (ACE) inhibitors and statins, the latter being an inhibitor 
of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase that produces 
mevalonate essential for membrane targeting of Ras and Rho family small GTPases.   
Transgenic mice that overexpressed SphK1 under a universal promoter developed 
spontaneous cardiomyocyte degeneration and fibrosis without hypertrophy, which 
started by 12 weeks and progressed with age [40]. SphK activity and S1P content in the 
transgenic heart were 20- and 1.7-fold elevated over those of the wild type littermates, 
respectively, without any change in sphingosine or ceramide content. Plasma and serum 
S1P levels were comparable to those in wild type mice. Transgenic mice grew up 
normally with normal blood pressure, blood cell counts and blood biochemistry. 
Transgenic heart tissues displayed increases in GTP-bound active forms of RhoA and 
Rac1, and an oxidative stress marker malondialdehyde. Administration of either an 
HMG CoA reductase inhibitor or an antioxidant N-2-mercaptopropyonylglycine nearly 
completely protected transgenic hearts from fibrosis, whereas an AT1R antagonist was 
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without any effect. Interestingly, cardiac fibrosis in SphK1-transgenic mice was 
substantially alleviated in S1P3-/- genetic background. SphK1-transgenic/S1P3+/+ heart 
tissues showed higher levels of Smad3 phosphorylation over SphK1-transgenic/S1P3-/- 
hearts, suggesting that activation of TGFβ signaling is involved in S1P3-dependent 
development of cardiac fibrosis. It is likely that basal TGFβ expression level in the 
myocardium was sufficient for S1P3-mediated amplification of TGFβ signaling, since 
increased expression of TGFβ in the myocardium of SphK1-transgenic mice was not 
observed. In ischemia/reperfusion injury experiments, SphK1-transgenic mice exhibited 
a reduction in infarcted area compared with wild-type mice. Thus, transgenic 
overexpression is also cardioprotective against acute ischemia/reperfusion injury. These 
observations altogether suggest that, in contrast to the beneficial effects of 
HDL-associated S1P which induces activation of endothelial S1P3-eNOS axis and 
myocardial S1P3-phosphatidylinositol 3-kinase (PI3K)-Akt axis, persistent and 
exaggerated stimulation of S1P3 in the myocardium leads to cardiac fibrosis in vivo 
through multiple mechanisms, which include transactivation of TGFβ signaling 
pathway and activation of RhoA and Rac1 small GTPases [41, 42] with downstream 
signaling involving reactive oxygen species (ROS) generation [43]. 
   According to the observations in cultured fibroblasts derived from other tissues [44, 
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45], TGFβ signaling could be located either upstream or downstream of S1P receptors 
in cardiac fibroblasts. S1P induced myofibroblast differentiation of murine CFs in a 
manner dependent on S1P2 and RhoA [46], while TGFβ stimulation upregulated both 
the expression and activity of SphK1 in CFs. Furthermore, the stimulatory effect of 
TGFβ on collagen expression was dependent upon SphK1 and S1P2, and inhibited by 
anti-S1P monoclonal antibody. Although crossing of the SphK1-transgenic mice with 
S1P2-null mice failed to produce double mutant mice in our laboratory, possible in vivo 
contribution of S1P2 in TGFβ-mediated cardiac fibrosis deserves further investigation. 
 
Pulmonary fibrosis 
Pulmonary fibrosis is an intractable lung disease with a high mortality rate [47]. 
Chronic inflammation due to viral infection, radiotherapy and inhalation of 
environmental toxic substances or epithelial injury of unknown cause underlie 
pulmonary fibrosis. Epithelial injury results in apoptotic cell death and/or abnormal 
activation of alveolar epithelial cells with the production of cytokines and other 
mediators, leading to infiltration of inflammatory cells and expansion of fibroblasts and 
myofibroblasts through proliferation and activation of resident fibroblasts, stimulation 
of EMT, and recruitment of circulating fibrocytes (Figure 3) [47-49]. Activated 
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myofibroblasts secrete excessive amounts of ECM, resulting in destruction of lung 
architecture.  
In recent years, there is growing evidence that S1P and another lysophospholipid 
mediator lysophosphatidic acid (LPA) are involved in the development of lung fibrosis. 
Lung fibroblasts express multiple lysophospholipid receptor subtypes including LPA1-3 
and S1P1-3, and respond to LPA and S1P with differentiation into myofibroblasts and 
stimulation of migration [10]. In fibroblasts LPA and S1P activate Cl- channel activity, 
which plays an important role in myofibroblast differentiation by the lysophospholipid 
mediators [50]. Tager et al. showed that LPA is a crucial factor in the progression of 
pulmonary fibrosis [51]. LPA was detected in bronchoalveolar lavage fluid (BALF) in 
patients with pulmonary fibrosis of unknown cause (idiopathic pulmonary fibrosis 
(IPF)). In bleomycin-induced lung fibrosis model of mice, LPA concentration in BALF 
was increased after bleomycin challenge. Mice lacking LPA1, which was the most 
abundant LPA receptor subtype in lung fibroblasts, was protected from 
bleomycin-induced pulmonary fibrosis and mortality, indicating a profibrotic role of 
LPA1. LPA1 deletion suppressed fibroblast recruitment and vascular leakage, which are 
pathogenically linked to pulmonary fibrosis, but did not alter leukocyte infiltration in 
bleomycin-treated mice. They also observed that fibroblasts obtained from patients with 
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IPF most abundantly express LPA1 among LPA-specific receptor subtypes and that 
pharmacological blockade of LPA1 abolished chemotaxis of fibroblasts toward LPA or 
BALF from IPF patients. LPA-LPA1 signaling also promoted apoptosis of epithelial 
cells in bleomycin-induced lung injury [52]: apoptosis of alveolar and bronchial 
epithelial cells after bleomycin challenge was attenuated in LPA1-deficinet mice 
compared with wild-type mice. In contrast, stimulation of LPA1 rendered lung 
fibroblasts resistant to apoptotic stimuli. Thus, this action of LPA1 allows fibroblasts to 
persist in areas of fibrosis. These results indicate that LPA signaling through LPA1 
contributes to development of pulmonary fibrosis through its actions on fibroblasts, 
vasculature and epithelial cells. In a mouse model of radiation-induced lung fibrosis, the 
content of LPA and the expression of LPA1 and LPA3 in the lung were increased [53]. 
The administration of LPA1/3 antagonist VPC12249 reduced fibroblast accumulation and 
collagen deposition in the lung, and increased mice survival. LPA2 is also implicated in 
lung fibrosis. LPA-LPA2 is engaged in the activation of TGF-β, which is a major 
fibrogenic cytokine in the pathogenesis of lung fibrosis [48, 49]. LPA2 is involved in 
αvβ6 integrin-mediated activation of TGF-β through Gq protein, RhoA, and Rho kinase 
in epithelial cells [54]. Expression levels of LPA2 receptor and αvβ6 integrin are 
upregulated in bleomycin-injured lung of mice and in lung fibrotic areas in patients with 
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interstitial pneumonia.  
These results suggest that LPA and its receptors are potential targets for treatment of 
pulmonary fibrosis. Recently, an orally available LPA1 antagonist AM966 has been 
demonstrated to protect mice against bleomycin-induced lung fibrosis [55]. This 
LPA1-antagonist alleviated bleomycin-induced lung injury including vascular leakage, 
inflammation and fibrosis, and reduced TGF-β1 level in BALF. Another orally available 
LPA1-selective antagonist AM095 also effectively attenuated bleomycin-induced 
increases in collagen accumulation and infiltrating inflammatory cells in BALF in mice 
[56]. More recently, the LPA1-selective antagonist AM152 was granted Orphan Drug 
Status by the FDA for the treatment of IPF [57].  
S1P has also been implicated in lung fibrosis although precise mechanisms of the 
S1P involvement are still ill-defined. A previous study [58] showed that bleomycin 
treatment of NIH3T3 cells led to an increase in cellular S1P level. The expression of 
SphK1 was increased in lung fibrotic regions in bleomycin-administered mice [59]. In 
patients with IPF, S1P levels in serum and BALF were increased compared with normal 
subjects and correlated with lung functions in IPF patients [60]. In lung tissues from IPF 
patients, increased expression of SphK1 protein was observed. These observations 
suggested that S1P may be involved in IPF. Fibroblasts mainly express S1P1, S1P2 and 
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S1P3 [60, 61]. S1P1 mediates migration and proliferation of mouse embryonic 
fibroblasts (MEFs) in response to S1P [62, 63]. In contrast, S1P2 mediate inhibition of 
chemoattractant-directed cell migration and proliferation in MEFs and human lung 
fibroblast HLF-1 cells [60-62]. Thus, the balance between S1P1 and S1P2 signaling 
seems to critically regulate recruitment and proliferation of fibroblasts in fibrotic lungs.  
Several recent studies suggest that S1P regulates myofibroblast differentiation: S1P 
induced αSMA expression and morphologic change in human lung fibroblasts WI38 in 
a manner dependent on Rho kinase but independent of pertussis toxin-sensitive Gi [64]. 
FTY720, whose phosphorylation product is a potent agonist for all S1P receptors except 
S1P2, induced myofibroblast differentiation of fibroblasts via S1P3 [10]. This FTY720 
effect was mediated by Smad3. On the other hand, TGFβ induced myofibroblast 
differentiation via S1P and its receptors. TGFβ1 treatment of human WI38 lung 
fibroblasts increased expression of αSMA and SphK1 [59]. SphK inhibition by chemical 
inhibitors or siRNA-mediated knockdown attenuated TGFβ1-induced upregulation of 
αSMA and fibronectin. Moreover, knockdown of either S1P2 or S1P3 but not S1P1 
inhibited TGFβ1-induced αSMA expression. The addition of the Rho kinase inhibitor 
Y27632 also suppressed TGFβ1-induced αSMA expression. Thus, TGFβ1 induced 
myofibroblast differentiation through SphK1-S1P2/S1P3-Rho kinase pathway.  
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Myofibroblasts in fibrotic lesions may also be derived from epithelial cells through 
EMT. S1P induced EMT in alveolar type II epithelial A549 cells via S1P2 and S1P3 [60]. 
S1P-induced EMT was dependent on TGFβ-Smad3 pathway, Rho-Rho kinase and ROS. 
TGFβ1-induced EMT was accompanied by the upregulation of SphK1 expression and 
partially mediated by SphK1, S1P2/S1P3, Rho kinase and ROS. Furthermore, a recent 
study [65] showed that genetic deletion of SphK1 protected mice from 
bleomycin-induced fibrosis and mortality with attenuated expression of αSMA, 
fibronectin and collagen, and phosphorylation of Smad2/3. These observations together 
suggest that the feed-forward cross-talk between S1P and TGFβ, which amplifies 
profibrotic signals, is existent.  
Previous studies demonstrated that S1P-S1P1 pathway enhances endothelial barrier 
function in vivo and in vitro [66]. Shea et al. showed that repeated administration of 
FTY720 or the S1P1-selective agonist AUY954 into mice increased vascular leak and 
mortality after bleomycin challenge [67]. Continued exposure to the S1P1 agonists also 
resulted in exacerbation of lung fibrosis. These observations, together with other studies 
[68, 69], indicate that S1P1-agonists can act as functional antagonists of S1P1 in vivo 
through the mechanism of S1P1-agonist-induced internalization and degradation of S1P1 
and consequently impair the barrier-protective function of S1P1 on endothelial cells. 
19 
 
These observations also suggest that vascular hyperpermeability is an important 
component of the fibrogenic responses to lung injury and point to the possibility that 
targeting endothelial S1P1 may be a useful therapeutic tactic.  
As described above, several reports suggested that S1P might be involved in lung 
fibrosis. However, compared with LPA, it remains ill-defined whether S1P is profibrotic 
or anti-fibrotic as an overall effect and by what exact mechanisms S1P could modify 
lung fibrosis. It is necessary to further explore the roles of S1P signaling pathway in 
lung fibrosis, particularly by utilizing specific inactivation of S1P receptor subtypes 
and/or modulation of SphK isoforms. The studies of patients with IPF showed that the 
signaling pathways of LPA and S1P may be stimulated in lung fibrotic lesions as 
suggested by increased levels of LPA and S1P in BALF, elevated expression of SphK1 
in lung fibrotic lesions and augmented chemotactic responses of fibroblasts from IPF 
patients [51, 60]. However, the available data are still limited, and whether LPA and S1P 
have a causal role in IPF awaits further investigation.  
 
Systemic sclerosis  
   Systemic sclerosis (scleroderma) is a connective tissue disease of unknown cause 
and is characterized by progressive extensive multi-organ fibrosis [70]. Fibrosis is most 
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prominent in the skin, lung, heart, kidney and gastrointestinal tract. The pathogenesis of 
systemic sclerosis involves interactions between vasculopathy, inflammation and 
autoimmunity, and fibrosis. As the earliest events, tissue injury by various insults 
including viral infection and oxidative stress may result in vascular injury. Vascular 
injury causes endothelial activation and dysfunction, leading to vascular permeability 
changes, increased endothelial expression of leukocyte adhesion molecules, altered 
secretion of vasoactive mediators, and platelet activation. These events result in 
leukocyte adhesion to the endothelium, platelet aggregation and thrombosis, vascular 
remodeling with intimal and medial hypertrophy, and eventually vascular obliteration 
with tissue hypoxia. The lesions at the early stage are also characterized by infiltration 
of T lymphocytes and monocytes. Release of cytokines and growth factors from the 
infiltrating leukocytes, activated endothelium and other cell types in the lesions induces 
further tissue damage and wound healing responses comprising recruitment of 
fibroblasts, myofibroblast differentiation, and ECM accumulation by the expanded pool 
of fibroblasts/myofibroblasts. Progressive fibrosis is the primary cause of death in 
systemic sclerosis and refractory to current therapy. Therefore, discovery of novel 
mediators to drive fibrogenesis is expected to provide effective therapeutic targets for 
progressive fibrosis in systemic sclerosis.     
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   Several lines of recent studies provided a rationale for the hypothesis that LPA and 
S1P might be new mediators for systemic sclerosis. Patients with systemic sclerosis 
exhibited elevated (2.2-fold) serum LPA levels compared with healthy subjects [71, 72]. 
However, serum activity of the key LPA-producing enzyme autotaxin and serum level 
of the LPA precursor lysophosphatidylcholine were not different between patients and 
control subjects, suggesting that elevated serum LPA in patients may be due to reduced 
degradation of LPA. Analysis of LPA species revealed that serum level of 
arachidonyl-LPA but not other LPA species was higher in systemic sclerosis patients. 
Arachidonyl-LPA is shown to have a relatively high platelet-activating potency and 
chemotactic activity for immature dendritic cells. The same study also demonstrated 
that serum level of S1P was approximately 1.4-fold increased in systemic sclerosis 
patients than in control subjects. Two other studies [73, 74] using dermal fibroblasts 
derived from systemic sclerosis patients demonstrated altered responses of fibroblasts to 
LPA and S1P. Fibroblasts from systemic sclerosis patients showed increased activity of 
LPA-activated Cl- channel, which is implicated in myofibroblast differentiation [50], 
and elevated αSMA expression compared with normal fibroblasts [73]. Fibroblasts from 
systemic sclerosis patients also showed decreased expression of S1P1/S1P2 and 
increased expression of S1P3, compared with normal fibroblasts [74]. S1P induced 
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phosphorylation of Smad3 via S1P1/S1P2 in systemic sclerosis fibroblasts whereas 
closely related S1P receptor agonist dihydro-S1P rather inhibited Smad3 
phosphorylation, although the molecular mechanism underlying the differential effects 
of S1P and dihydro-S1P was unknown.  
Subcutaneous injection of bleomycin in mice, which is a commonly used animal 
model for dermal fibrosis in systemic sclerosis, induces collagen accumulation in the 
skin [70]. Bleomycin-induced dermal thickening and collagen accumulation was nearly 
abrogated in LPA1-KO mice but not LPA2-KO mice [75]. Subcutaneous bleomycin 
injection stimulated Smad 2 phosphorylation and αSMA expression in the dermis. 
Stimulation of dermal Smad2 phosphorylation and αSMA expression was markedly 
inhibited in LPA1-KO mice, indicating the contribution of LPA1 to activation of 
TGFβ/Smad pathway and fibrosis in the skin. Administration of the LPA1-selective 
antagonist AM095 markedly inhibited bleomycin-induced dermal fibrosis. In addition, 
S1P and LPA may be involved in vasculopathy, autoimmunity and inflammation in 
systemic sclerosis through their actions on vascular endothelium, inflammatory cells 
including macrophages and mast cells, and immune cells [11, 16, 76].  
In summary, these observations suggest that LPA/S1P signaling have the potential as 





Irrespective of the insults, such as virus, alcohol abuse or drugs, the wound healing 
response generally occurs in the liver upon injury, and the persistence of this response 
may result in liver fibrosis. It is now well known that among the cells in the liver, 
hepatic stellate cells play a major role in liver fibrosis (Figure 4). During the process of 
liver fibrosis, hepatic stellate cells undergo a phenotypic change to myofibroblasts. This 
change has been termed as activation, in which enhanced proliferation, extracellular 
matrices production, contractility and motility are among its main features [77-79]. 
Many fibrogenic factors in the liver such as TGFβ or PDGF have been evaluated with a 
focus on the effects on this hepatic stellate cell activation [79].  
Regarding hepatic stellate cells and S1P, S1P was first shown to stimulate rat hepatic 
stellate cell proliferation via an extracellular mechanism, suggesting that S1P could be a 
pro-fibrogenic factor in the liver [80]. However, the contrary finding of antiproliferative 
properties of S1P as an intracellular mediator was reported in human hepatic 
myofibroblats [81]. Although the discrepancy between these two results in vitro has not 
been solved yet, whether S1P might be pro-fibrogenic or anti-fibrogenic in the liver was 
later determined with S1P receptor-deficient mice in vivo. In mice, deletion of S1P1 is 
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known to result in embryonic lethality, while deletion of S1P2- or S1P3-deleted mice are 
viable and cause no obvious abnormality in the liver [82]. However, once acute liver 
injury was induced in S1P2-deficient mice, a response of hepatic stellate cells (or 
hepatic myofibroblasts) to the insult was dramatically affected, in which the wound 
healing responses determined by accumulation of hepatic myofibroblasts was 
profoundly reduced. Furthermore, S1P enhanced proliferation of cultured hepatic 
myofibroblasts from wild-type mice but not those from S1P2-deficient mice [83]. These 
results suggest a pro-fibrogenic property of S1P via S1P2 in the liver. Indeed, liver 
fibrosis caused by repeated administration of carbon tetrachloride was shown to be 
reduced in S1P2-deficient mice, suggesting that S1P plays a stimulatory role in liver 
fibrosis via S1P2 [84]. It has been shown that S1P2 is preferentially coupled to G12/13 and 
hence Rho [85]. In line with this, the enhancement of Rho and Rho kinase activity in the 
liver during the process of fibrosis after bile duct ligation was reduced in S1P2-deficient 
mice [86]. Collectively, the contribution of S1P to the progress of liver fibrosis may be 
mediated by Rho and Rho kinase activation via S1P2. 
Recently, a potential role of bone marrow-derived cells in liver fibrosis is gaining 
attention. There are a number of studies reporting that bone marrow-derived cells 
migrate into the liver, transdifferentiate to hepatic myofibroblasts and may participate in 
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the progress of liver fibrosis. In contrast, it has also been shown that bone 
marrow-derived cells in the liver contribute to the regression of liver fibrosis. Thus, 
controversy exists regarding the role of bone marrow-derived cells in liver fibrosis [87]. 
From the standpoint of bone marrow-derived cells as pro-fibrogenic cells, S1P was 
shown to play an important role in the progress of liver fibrosis caused by bile duct 
ligation [88] or repeated administration of carbon tetrachloride [89] to mediate bone 
marrow-derived cell migration into the liver. These effects were shown to be exerted via 
S1P3, because suramin as S1P3 antagonist attenuated the pro-fibrogenic effect of S1P 
[88, 89]. Furthermore, the contribution of S1P1 and S1P3 to S1P-induced migration was 
reported in human hepatic stellate cell line [90] or human hepatic myofibroblasts [91]. 
Thus, so far there are two lines of evidence showing that S1P is pro-fibrogenic, and the 
exact contribution of S1P receptors, S1P1, S1P2 and S1P3, to liver fibrosis should be 
further elucidated.  
Because hepatic stellate cells reside around hepatic sinusoid, which is unique 
vasculature in the liver, contraction of those cells results in increased pressure of hepatic 
sinusoid and hence of portal vein, which is linked to hepatic sinusoid. Thus, it has been 
speculated that hepatic stellate cells may play a direct role in the pathogenesis of portal 
hypertension, one of major complications of liver fibrosis. S1P was shown to enhance 
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contractility of hepatic stellate cells in vitro [80], and further to increase portal vein 
pressure ex vivo in rats with Rho and Rho kinase activation via S1P2 [92]. Furthermore, 
it has been recently shown that the intravenous administration of S1P2 antagonist, 
JTE-013, promptly reduces portal vein pressure with Rho kinase inactivation in rats 
with portal hypertension caused by bile duct ligation [86]. It should be noted that this 
effect of S1P2 antagonist is selective for portal vein pressure in rats with portal 
hypertension, which may be explained by selective enhancement of S1P2 expression in 
stellate cells of the liver. These results suggest that S1P importantly contributes to the 
pathophysiology of portal hypertension via S1P2, and that S1P2 antagonist merits 
consideration as a therapeutic agent for portal hypertension. 
Regarding S1P level in the blood stream in liver fibrosis, plasma S1P level was 
shown to be reduced, and the inverse correlation was revealed between serum 
hyaluronic acid level, a marker of liver fibrosis, and plasma S1P level in patients with 
chronic hepatitis C, suggesting that plasma S1P level may be reduced during the process 
of liver fibrosis. In line with this speculation, plasma S1P level was shown to be reduced 
in association with the progress of liver fibrosis in rats with carbon tetrachloride 
administration [93]. It is established that red blood cells and platelets contribute 
importantly to the regulation of plasma S1P level [94, 95]. In addition, liver may be also 
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substantially involved in the regulation of plasma S1P level. 
 The dynamic change of plasma S1P level and S1P receptors expressions in the 
liver in the process of liver fibrosis and the substantial effect of S1P receptor knockout 
on liver fibrosis have been described. Although all these findings strongly suggest an 
important role of S1P in the pathophysiology of liver fibrosis, little is known regarding 
the signaling pathways operating in the liver so far. Thus, this point should be elucidated 
in the future, and also the therapeutic strategy for liver fibrosis focusing on the 
regulation of S1P effects should be further established. 
 
Conclusion and perspectives 
Emerging evidence highlights the new role of S1P signaling pathway in fibrosis, 
which is often associated with chronic inflammation. The previous studies using mouse 
models of fibrosis suggest that S1P may affect fibrogenesis through affecting vascular 
barrier function, inflammatory cell recruitment, and migration, proliferation and 
myofibroblast differentiation of fibroblasts. S1P could exert receptor subtype-specific, 
distinct effects on each of these processes. In fibrotic lesions, a variety of cytokines and 
mediators may regulate expression and activity of SphKs, thereby altering S1P 
production. However, it remains undefined what roles locally produced and blood S1P 
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plays in fibrogenesis, respectively. Moreover, S1P signaling pathway seems to 
cross-talk with TGFβ signaling pathway at multiple steps. This cross-talk amplifies 
cellular mechanisms for stimulating fibrogenesis. Details in cellular and molecular 
mechanisms underlying S1P regulation of fibrogenesis still remain to be clarified. 
Information concerning the role of the lysophospholipid mediators in human fibrotic 
diseases is scarce. In addition, it is necessary to reveal similarities and dissimilarities in 
human fibrotic diseases and animal models of fibrosis, because most of animal data on 
the pathogenesis of fibrotic diseases were obtained using particular animal models of 
each fibrotic disease. Nevertheless, available evidence demonstrates that 
lysophospholipid signaling pathways of S1P and also LPA are novel, promising 
therapeutic targets for treating fibrotic diseases.  
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Figure 1. Myofibroblastic differentiation and production of extracellular matrix 
and cytokines by myofibroblasts. Activated fibroblasts or myofibroblasts are derived 
from several different sources including resident stromal fibroblasts, epithelial cells 
(epithelial-mesenchymal transition (EMT)), endothelial cells (endothelial-mesenchymal 
transition (EndMT)), and bone marrow-derived fibrocytes. Myofibroblasts synthesize 
and deposit ECM components, which mainly include collagen type I and smaller 
amounts of collagen type III, fibronectin, elastin, laminin, proteoglycan and 
glycosaminoglycan, and release various cytokines and mediators, which stimulate 
myofibroblasts in a paracrine manner. Infiltrating inflammatory cells, parenchymal cells 
and other cells also release cytokines and mediators. TGFβ, transforming growth 
factor-β; IL-6, interleukin-6; Ang II, angiotensin II. 
 
Figure 2. Receptor subtype-specific cardioprotective and cardio-damaging effects 
of S1P. S1P exerts a cardioprotective effect through S1P3-mediated eNOS stimulation in 
endothelial cells (EC) and generation of Akt-mediated survival signal in cardiomyocytes 
(CM). This effect is a relatively quick response. In contrast, S1P induces cardiac 
remodeling (myocardial cell death and cardiac fibrosis) through S1P3/S1P2-mediated 
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Rho GTPase activation and transactivation of TGFβ signaling pathway. TGFβ 
stimulates SphK1 to increase S1P production, which further exacerbates cardiac damage. 
The transactivation of TGFβ signaling pathway by S1P3 and stimulation of SphK1 by 
TGFβ constitute a feed-forward amplifying signaling loop, which leads to cardiac 
damage. PLC, phospholipase C; PI3K, phosphatidylinositol 3-kianse; MFb, 
myofibroblast. 
 
Figure 3. Pathologic fibrotic response to lung injury and its modulation by S1P. 
Damage to lung epithelial cells is associated with apoptosis of epithelial cells, the loss 
of epithelial/endothelial barrier, resulting in re-epithelialization and increased vascular 
permeability. Apoptotic cells, recruited inflammatory cells, or abnormally activated 
alveolar epithelial cells produce mediators that induce the formation of fibroblasts and 
myofibroblasts through the proliferation of resident mesencymal cells, recruitment of 
circulating fibrocytes, and stimulation of EMT. Activated myofibroblasts secrete 
excessive amounts of ECM, mainly collagen, resulting destruction of lung architecture. 
Growing evidence suggest the role of S1P in vascular barrier protection, regulation of 
migration and proliferation of fibroblasts and myofibroblast differentiation (boxed). 
LPA is also implicated in lung fibrosis through mechanisms involving epithelial 
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damaging and vascular barrier disruption.  
 
Figure 4. Involvement of hepatic stellate cells in liver fibrosis and its regulation by 
S1P receptors. Various liver injury results in liver fibrosis. Hepatic stellate cells, 
pericytes of sinusoid, play a major role in liver fibrosis. During the process of liver 
fibrosis, hepatic stellate cells proliferate and undergo differentiation into myofibroblasts, 
which produce extracellular matrix proteins. S1P is involved in these processes 
primarily via S1P2. S1P2 also mediates contraction of stellate cells, resulting in portal 
hypertension. S1P1 and S1P3 may also be involved in myofibroblast differentiation and 
activation through stimulating proliferation and migration. Another source of 
myofibroblasts in the fibrotic liver is circulationg bone marrow-derived fibrocytes, 
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